Results 241 to 250 of about 24,065 (296)

The c-di-GMP effector FleQ controls alginate production by repressing transcription of <i>algD</i> in <i>Azotobacter vinelandii</i>. [PDF]

Microbiology (Reading)
Barrios-Rafael VV, Ahumada-Manuel CL, Orgaz-Ramírez S, Nava-Galeana J, Guzmán J, Moreno S, Bustamante VH, Núñez C.   +7 more
europepmc   +1 more source

Trajectories of medication for opioid use disorder and their impact on HIV testing among people who inject drugs in India: A longitudinal assessment of clinic‐based data

Addiction, Volume 120, Issue 4, Page 745-755, April 2025.
Abstract Aims The aim of this study was to identify longitudinal trajectories of medication for opioid use disorder (MOUD) use throughout 1 year following MOUD initiation and to examine the association of trajectory membership with HIV testing among people who inject drugs in India.
Allison M. McFall, Lakshmi Ganapathi, Mihili P. Gunaratne, Aylur K. Srikrishnan, Conjeevaram K. Vasudevan, Santhanam Anand, Sunil S. Solomon, Shruti H. Mehta, Gregory M. Lucas   +8 more
wiley   +1 more source

Deciphering ligand and metal ion dependent intricate folding landscape of Vc2 c-di-GMP riboswitch aptamer. [PDF]

Nucleic Acids Res
Shin JY, Choi SR, An SY, Bang KM, Song HK, Suh JY, Kim NK.   +6 more
europepmc   +1 more source

Novel Progress in Limbal Stem Cell Transplantation

Organ Medicine, EarlyView.
Liqin Huang, Liangbo Chen
wiley   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

How c-di-GMP controls progression through the Streptomyces life cycle. [PDF]

Curr Opin Microbiol
Gallagher KA, Tschowri N, Brennan RG, Schumacher MA, Buttner MJ.   +4 more
europepmc   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

A novel transcriptional regulator, CdeR, modulates the type III secretion system via c-di-GMP signaling in <i>Dickeya dadantii</i>. [PDF]

Microbiol Spectr
Ghasemi A, Yuan X, Yang C-H.
europepmc   +1 more source

A Case for Anti‐IgE Vaccination

Allergy, EarlyView.
ABSTRACT Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high‐affinity receptor FcεRI on mast cells and basophils, where allergen‐induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research.
Paul Engeroff, Zahra Gharailoo, Monique Vogel, Martin F. Bachmann   +3 more
wiley   +1 more source